Physician

Sandhya Bejjanki, M.D.

According to 2025 Medicare claims, Sandhya Bejjanki, M.D. (NPI: 1205037488) practices hematology/oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Johnson, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 76033-4033. Bejjanki is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Bejjanki's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 300 traditional Medicare patients, billed 106,875 HCPCS/CPT codes, and received $1,869,675 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,090 prescription claims across 205 beneficiaries totaling $2,470,604 in drug costs, led by Calquence (Acalabrutinib Maleate). DME data shows 11 claims. Open Payments data shows 38 records totaling $804. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,354,455 and ending at $1,869,675. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $437,906 to $2,470,604. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.